00000cam a22000004i 4500 UP-99796217611795962 Buklod 20150930085250.0 a r |||| u| ta 141106s2015 nyua rb |001 0|eng d 9781621820833 (hardback) (iLib)UPD-00249809066 DLC DNIMBB rda eng K 1519 B54 I584 2015 Intellectual property in molecular medicine edited by Salim Mamajiwalla, Rochelle Seide. Cold Spring Harbor, New York Cold Spring Harbor Laboratory Press [2015] ix, 289 pages color illustrations 26 cm text rdacontent unmediated rdamedia volume rdacarrier "A subject collection from Cold Spring Harbor perspectives in medicine." Includes bibliographical references and index. Machine generated contents note: -- (preliminary) -- 1. Introduction to Intellectual Property: A US Perspective -- Amanda Murphy, Michael Stramiello, Tom Irving, and Stacy Lewis -- 2. Impact of America Invents Act on Biotech Intellectual Property -- Amanda Murphy, Michael Stramiello, Tom Irving, and Stacy Lewis -- 3. Patenting the Life Sciences at the European Patent Office -- Christina Gates -- 4. The Role of Regulatory Agencies and Intellectual Property -- Kevin Noonan -- 5. Regulatory Law and Intellectual Property in Europe -- Anne Bateman -- 6. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property -- Henry Bian and Conor McCourt -- 7. Inventorship and Authorship -- Antoinette F. Konski -- 8. Must an Inventor "Possess" an Invention to Patent It? -- Warren D. Woessner and Robin A. Chadwick. 9. What is Your Reasonable Expectation of Success in Obtaining Pharmaceutical or Biotechnology Patents Having Non-Obvious Claimed Inventions that Will courts Will Uphold? An Overview of Obviousness Court Decisions -- Daniel Pereira and Stephen G. Kunin -- 10. Inherent Anticipation in Pharma and Biotech -- Michael Goldman, Georgia Evans, and Andrew Zappia -- 11. Baseball Bats and Chocolate Chip Cookies: The Judicial Treatment of DNA in the Myriad Genetics Litigation -- Ian Binnie and Vanessa Park-Thompson -- 12. Patentability of Genes: An EU Perspective -- Paul Cole -- 13. Decoding Gene Patents in Australia -- Adam Denley and James Cherry -- 14. The Impact of Myriad and Mayo: Will Advancements in the Biological Sciences be Spurred or Disincentivized? (Or, Wasn't Biotech Patenting Complicated Enough?) -- Jennifer Gordon. 15. The Impact of Myriad on the Future Development and Commercialization of DNA-Based Therapies and Diagnostics -- Michele Wales -- 16. Research Use Exemptions to Patent Infringement for Drug Discovery and Development in the United States -- Alicia A. Russo and Jason Johnson -- 17. Research Exemption / Experimental Use in the EU: Patents Do Not Block the Progression of Science -- Hans-Rainer Jaenichen and Johann Pitz -- 18. Patenting Stem Cell Technologies in the US -- Donald L. Zuhn -- 19. Patenting Stem Cell Technologies in Europe -- Andrew Sheard -- 20. The Patentability of Stem Cells in Australia -- Jenny Petering and Prue Cowin -- 21. Patentability of Self-Replicating Technologies -- Richard H. Shear -- 22. Protecting Traditional Knowledge Related to Biological Resources: Is Scientific Research Going to Become More Bureaucratized? -- Prashant Reddy and Malathi Lakshmikumaran -- 23. Licensing Biotech IP in University Industry Partnerships -- Vladimir Drozdoff and Daryl Fairbairn -- 24. Trade Secrets in Life Science and Pharmaceutical Companies -- Tara Nealey, Ronald M. Daignault, and Yu Cai -- 25. Trade Secrets in Canada -- Noel Courage and Janice Calzavara. Biotechnology Patents. Intellectual property. Molecular biology. Mamajiwalla, Salim editor. Seide, Rochelle K. editor. FO UPD DIMBB K 1519 B54 I584 2015 Book